May 30th Highlights

• Foul Play in Canada - Canadian cannabis companies formally cried foul about their rivals’ business practices nearly 200 times last year, the highest number of complaints lodged with Health Canada in years and nearly double 2019 levels. This very revealing read explores the issues with the Candian market that are causing companies to operate in grey areas to grow. Article link
• A Change in Sentiment - Data from a recent survey of 1506 family medical professionals demonstrated that 70 percent of clinicians believe cannabis has therapeutic value. Over time more doctors are adopting cannabis into their treatment wheelhouse. In Australia, a recept report stated that across Australia, there are now more than 180 number of Authorised Prescribers in Australia - an Authorised Prescriber is allowed to supply the product directly to patients in their immediate care without requiring separate approval for individual patients. Between July 1 - Dec 31 2020 Authorised Prescribers prescribed cannabis to more than 7,500 new patients.
• Italian Industry Speaks up to Parliament - A collective of Italian cannabis operators spoke out against an anti-cannabis ‘manifesto’ presented by an Italian politician. The group rightfully commented that  “We are in a historical and economic moment that sees many Italian companies in difficulty. Talking about our work in these terms does not bring any help. On the contrary, it blocks one of the few sectors that, despite the total absence of incentives and concessions, has been able to resist and grow,” Cathy La Torre. This is an excellent example of businesses speaking out against unfounded anti-cannabis agendas that block the industry from growing. Reference link
• Progress in the Field of Glioblastoma - A phase 2 randomised clinical trial with 88 patients assessed the tolerability of two different ratios of medicinal cannabis in patients with high-grade gliomas. The study demonstrated that a single nightly dose of THC-containing medicinal cannabis was safe, had no serious adverse effects, and was well tolerated in patients. Medicinal cannabis significantly improved sleep, functional wellbeing, and quality of life. Study reference

A wonderful example - NZ’s first “Carbonzero” medical cannabis firm emerges

PBS & private health cover for legal medical cannabis

Lifespot Health launches Medihale inhaler to medical cannabis market in Australian first

AusCann reports medicinal cannabis dog trial results promising

Little Green Pharma receives $2.5M purchase order from DEMECAN

Avecho Biotechnology completes pharmaceutical CBD capsule

ACT reps give evidence to Victorian cannabis inquiry